Fulan Guan, PhD
Associate Research Scientist in PharmacologyDownloadHi-Res Photo
Cards
Appointments
Pharmacology
Primary
Additional Titles
Visiting Research Scientist
Contact Info
Appointments
Pharmacology
Primary
Additional Titles
Visiting Research Scientist
Contact Info
Appointments
Pharmacology
Primary
Additional Titles
Visiting Research Scientist
Contact Info
About
Copy Link
Titles
Associate Research Scientist in Pharmacology
Visiting Research Scientist
Appointments
Pharmacology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Guangzhou University of Traditional Chinese Medici (2002)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Fulan Guan's published research.
Publications Timeline
A big-picture view of Fulan Guan's research output by year.
Yung-Chi Cheng, PhD
Caroline Helen Johnson, PhD
Jorge Galán, PhD, DVM
María Lara-Tejero, DVM, PhD
Rong Hu
Former YSM
12Publications
652Citations
Publications
2023
YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
Lam W, Arammash M, Cai W, Guan F, Jiang Z, Liu S, Cheng P, Cheng Y. YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy. Frontiers In Pharmacology 2023, 14: 1244655. PMID: 37860121, PMCID: PMC10582333, DOI: 10.3389/fphar.2023.1244655.Peer-Reviewed Original ResearchCitationsAltmetric
2021
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, Cai W, Cheng W, Liu SH, Cheng P, Cai Y, Rattray NJW, Johnson CH, Chen L, Cheng YC. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports 2021, 11: 13482. PMID: 34188068, PMCID: PMC8242098, DOI: 10.1038/s41598-021-91623-3.Peer-Reviewed Original ResearchCitationsAltmetricProspective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
Wu J, Sun B, Hou L, Guan F, Wang L, Cheng P, Scobell S, Cheng YC, Lam W. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China. Frontiers In Pharmacology 2021, 11: 615287. PMID: 33716728, PMCID: PMC7947616, DOI: 10.3389/fphar.2020.615287.Peer-Reviewed Original ResearchCitationsAltmetric
2020
Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging
Hou S, He S, Xie J, Li M, Hong M, Guan F, Hu Y, Huang Y, Xu C. Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging. Spectrochimica Acta Part A Molecular And Biomolecular Spectroscopy 2020, 235: 118315. PMID: 32289732, DOI: 10.1016/j.saa.2020.118315.Peer-Reviewed Original ResearchCitations
2018
Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
Lam W, Ren Y, Guan F, Jiang Z, Cheng W, Xu CH, Liu SH, Cheng YC. Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906). Frontiers In Pharmacology 2018, 09: 1324. PMID: 30510512, PMCID: PMC6252377, DOI: 10.3389/fphar.2018.01324.Peer-Reviewed Original ResearchCitationsAltmetricExploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles.
Tan Y, Lu C, Jiang M, Zhao N, Li L, Shen S, Guan F, He B, Xiao C, L A, Cheng S, Zu X, Zhang W, Liu X. Exploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles. Journal Of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association Of Traditional Chinese Medicine, Academy Of Traditional Chinese Medicine 2018, 38: 773-780. PMID: 32185996.Peer-Reviewed Original Research
2016
Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70
Wang Y, Lam W, Chen SR, Guan FL, Dutchman GE, Francis S, Baker DC, Cheng YC. Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70. Scientific Reports 2016, 6: 32832. PMID: 27596272, PMCID: PMC5011780, DOI: 10.1038/srep32832.Peer-Reviewed Original ResearchCitationsAltmetricAntibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates
Tsou LK, Lara-Tejero M, RoseFigura J, Zhang ZJ, Wang YC, Yount JS, Lefebre M, Dossa PD, Kato J, Guan F, Lam W, Cheng YC, Galán J, Hang HC. Antibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates. Journal Of The American Chemical Society 2016, 138: 2209-2218. PMID: 26847396, PMCID: PMC4831573, DOI: 10.1021/jacs.5b11575.Peer-Reviewed Original ResearchCitationsAltmetric
2014
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complementary Medicine And Therapies 2014, 14: 490. PMID: 25510341, PMCID: PMC4302098, DOI: 10.1186/1472-6882-14-490.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsAnimalsAnti-Bacterial AgentsAntineoplastic Agents, PhytogenicBacteriaCamptothecinColonic NeoplasmsDrugs, Chinese HerbalFemaleGranulocyte Colony-Stimulating FactorHumansIntestinal MucosaIntestinesIrinotecanMiceNeutrophil InfiltrationPhytotherapyReceptors, G-Protein-CoupledRNA, MessengerTumor Necrosis Factor-alphaWeight Loss
2013
PHY906, a Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues
Kong A, Lam, Bussom S, Jiang Z, Zhang W, Guan F, Liu S, Cheng Y. PHY906, a Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues. 2013, 549-562. DOI: 10.1201/b15323-38.Books
Get In Touch
Copy Link
Contacts
Email